| scholarly article | Q13442814 |
| P50 | author | Jacek Kubica | Q49506302 |
| Jolanta M Siller-Matula | Q37837348 | ||
| Max-Paul Winter | Q41577394 | ||
| Marek Koziński | Q68692877 | ||
| P2093 | author name string | Daniel Aradi | |
| P2860 | cites work | Impact of CYP2C19 polymorphism on residual platelet reactivity in patients with coronary heart disease during antiplatelet therapy | Q82942386 |
| Paraoxonase-1 is a major determinant of clopidogrel efficacy | Q82951856 | ||
| The influence of CYP2C19*2 and *17 on on-treatment platelet reactivity and bleeding events in patients undergoing elective coronary stenting | Q83194960 | ||
| A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reac | Q83944505 | ||
| Multiple electrode aggregometry and vasodilator stimulated phosphoprotein-phosphorylation assay in clinical routine for prediction of postprocedural major adverse cardiovascular events | Q84198897 | ||
| Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study | Q84567862 | ||
| High on-treatment platelet reactivity after prasugrel loading dose and cardiovascular events after percutaneous coronary intervention in acute coronary syndromes | Q84582096 | ||
| Relationship between post-treatment platelet reactivity and ischemic and bleeding events at 1-year follow-up in patients receiving prasugrel | Q84729330 | ||
| Residual platelet reactivity after aspirin and clopidogrel treatment predicts 2-year major cardiovascular events in patients undergoing percutaneous coronary intervention | Q84956961 | ||
| Prasugrel overcomes high on-clopidogrel platelet reactivity in chronic coronary artery disease patients more effectively than high dose (150 mg) clopidogrel | Q85063699 | ||
| Antiplatelet effects of prasugrel vs. double clopidogrel in patients on hemodialysis and with high on-treatment platelet reactivity | Q85068323 | ||
| Impaired responsiveness to the platelet P2Y12 receptor antagonist clopidogrel in patients with type 2 diabetes and coronary artery disease | Q85253139 | ||
| Bedside monitoring to adjust antiplatelet therapy for coronary stenting | Q85345517 | ||
| High on-treatment platelet reactivity--definition and measurement | Q86174316 | ||
| Comparison of antiplatelet effects of prasugrel and ticagrelor in cynomolgus monkeys by an ELISA-based VASP phosphorylation assay and platelet aggregation | Q87175690 | ||
| High rates of prasugrel and ticagrelor non-responder in patients treated with therapeutic hypothermia after cardiac arrest | Q87331363 | ||
| Overview of pleiotropic effects of platelet P2Y12 receptor inhibitors | Q87749253 | ||
| Central role of the P2Y12 receptor in platelet activation | Q24618777 | ||
| Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding | Q26829251 | ||
| Response variability to P2Y12 receptor inhibitors: expectations and reality | Q26999243 | ||
| Structure of the human P2Y12 receptor in complex with an antithrombotic drug | Q27682517 | ||
| Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction | Q28168881 | ||
| Association of a functional polymorphism in the clopidogrel target receptor gene, P2Y12, and the risk for ischemic cerebrovascular events in patients with peripheral artery disease | Q28176445 | ||
| Stent thrombosis is associated with an impaired response to antiplatelet therapy | Q28176582 | ||
| Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study | Q28193340 | ||
| Platelet activation predicts recurrent ischemic events after percutaneous coronary angioplasty: a 6 months prospective study | Q28193902 | ||
| High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome | Q28194081 | ||
| Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance | Q28194249 | ||
| Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity | Q28196405 | ||
| Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation | Q28196513 | ||
| Insulin therapy is associated with platelet dysfunction in patients with type 2 diabetes mellitus on dual oral antiplatelet treatment | Q28199546 | ||
| Platelet function in patients with acute coronary syndrome (ACS) predicts recurrent ACS | Q28200553 | ||
| Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis | Q28213327 | ||
| Resistance to antiplatelet drugs: molecular mechanisms and laboratory detection | Q28218540 | ||
| High post-treatment platelet reactivity is associated with a high incidence of myonecrosis after stenting for non-ST elevation acute coronary syndromes | Q28218589 | ||
| Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate? | Q28218910 | ||
| Thienopyridines in cardiovascular disease: focus on clopidogrel resistance | Q28219790 | ||
| Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives | Q28222158 | ||
| Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease | Q28222643 | ||
| Ticagrelor versus clopidogrel in patients with acute coronary syndromes | Q29619002 | ||
| The Residual Platelet Aggregation after Deployment of Intracoronary Stent (PREDICT) score. | Q33303244 | ||
| Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents | Q33335010 | ||
| A novel modification of the Thrombelastograph assay, isolating platelet function, correlates with optical platelet aggregation | Q33360658 | ||
| Early but not late stent thrombosis is influenced by residual platelet aggregation in patients undergoing coronary interventions | Q33509256 | ||
| Impact of inflammatory markers on platelet inhibition and cardiovascular outcome including stent thrombosis in patients with symptomatic coronary artery disease | Q33667980 | ||
| Pharmacokinetic, pharmacodynamic and clinical profile of novel antiplatelet drugs targeting vascular diseases | Q33685876 | ||
| Tailored antiplatelet therapy can overcome clopidogrel and aspirin resistance--the BOchum CLopidogrel and Aspirin Plan (BOCLA-Plan) to improve antiplatelet therapy | Q33791290 | ||
| Interplay between genetic and clinical variables affecting platelet reactivity and cardiac adverse events in patients undergoing percutaneous coronary intervention | Q33933475 | ||
| High residual platelet reactivity after clopidogrel loading and long-term clinical outcome after drug-eluting stenting for unprotected left main coronary disease | Q43240996 | ||
| Predictive values of post-treatment adenosine diphosphate-induced aggregation and vasodilator-stimulated phosphoprotein index for stent thrombosis after acute coronary syndrome in clopidogrel-treated patients | Q43267576 | ||
| Influence of C3435T multidrug resistance gene-1 (MDR-1) polymorphism on platelet reactivity and prognosis in patients with acute coronary syndromes | Q43270415 | ||
| Comparison of omeprazole and pantoprazole influence on a high 150-mg clopidogrel maintenance dose the PACA (Proton Pump Inhibitors And Clopidogrel Association) prospective randomized study | Q43275236 | ||
| Predictive value of post-treatment platelet reactivity for occurrence of post-discharge bleeding after non-ST elevation acute coronary syndrome. Shifting from antiplatelet resistance to bleeding risk assessment? | Q43279859 | ||
| Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis | Q43416611 | ||
| Platelet hyperactivity and abnormal Ca(2+) homeostasis in diabetes mellitus | Q43541597 | ||
| Regulation of protein kinase C by short term hyperglycaemia in human platelets in vivo and in vitro. | Q43554882 | ||
| Impact of preoperative use of P2Y12 receptor inhibitors on clinical outcomes in cardiac and non-cardiac surgery: A systematic review and meta-analysis | Q43740353 | ||
| Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes | Q43815690 | ||
| High on-treatment platelet reactivity to both aspirin and clopidogrel is associated with the highest risk of adverse events following percutaneous coronary intervention | Q43989417 | ||
| Residual platelet reactivity, bleedings, and adherence to treatment in patients having coronary stent implantation treated with prasugrel | Q44305048 | ||
| Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patien | Q44475877 | ||
| Platelet reactivity to adenosine diphosphate and long-term ischemic event occurrence following percutaneous coronary intervention: a potential antiplatelet therapeutic target | Q44479790 | ||
| Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects. | Q44545487 | ||
| Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity | Q44642265 | ||
| Clopidogrel and bleeding in patients undergoing elective coronary artery bypass grafting | Q45049123 | ||
| Ticagrelor induces adenosine triphosphate release from human red blood cells | Q45158070 | ||
| Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study | Q45287859 | ||
| Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome. | Q45947797 | ||
| The CYP2C19*17 allele is associated with better platelet response to clopidogrel in patients admitted for non-ST acute coronary syndrome. | Q45982700 | ||
| Glycoprotein IIb/IIIa inhibitors improve outcome after coronary stenting in clopidogrel nonresponders: a prospective, randomized study. | Q46000153 | ||
| Evaluation of the Platelet Mapping Assay on rotational thromboelastometry ROTEM. | Q46113377 | ||
| Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDA-PRO (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platele | Q46119763 | ||
| Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention | Q46133343 | ||
| Platelet concentrates transfusion in cardiac surgery and platelet function assessment by multiple electrode aggregometry | Q46142958 | ||
| Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up | Q46178120 | ||
| Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis | Q46187200 | ||
| Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel | Q46199177 | ||
| Impact of clopidogrel resistance on thrombotic events after percutaneous coronary intervention with drug-eluting stent | Q46223773 | ||
| Calcium-channel blockers reduce the antiplatelet effect of clopidogrel | Q46248005 | ||
| Effects of aspirin and clopidogrel in healthy men measured by platelet aggregation and PFA-100. | Q46367587 | ||
| Incidence and clinical impact of dual nonresponsiveness to aspirin and clopidogrel in patients with drug-eluting stents. | Q46418076 | ||
| A point-of-care platelet function assay and C-reactive protein for prediction of major cardiovascular events after drug-eluting stent implantation | Q46531708 | ||
| Relation of low response to clopidogrel assessed with point-of-care assay to periprocedural myonecrosis in patients undergoing elective coronary stenting for stable angina pectoris | Q46543532 | ||
| Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study | Q46665436 | ||
| Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation | Q46761762 | ||
| Dual non-responsiveness to antiplatelet treatment is a stronger predictor of cardiac adverse events than isolated non-responsiveness to clopidogrel or aspirin | Q46782610 | ||
| Monitoring of clopidogrel-related platelet inhibition: correlation of nonresponse with clinical outcome in supra-aortic stenting | Q46789035 | ||
| Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST Study | Q46802481 | ||
| Platelet inhibition by insulin is absent in type 2 diabetes mellitus | Q46843983 | ||
| Prasugrel versus clopidogrel in patients with acute coronary syndromes | Q46915044 | ||
| Clinical implications of very low on-treatment platelet reactivity in patients treated with thienopyridine: the POBA study (predictor of bleedings with antiplatelet drugs). | Q47723344 | ||
| Multiple electrode whole-blood aggregometry and bleeding in cardiac surgery patients receiving thienopyridines | Q48303367 | ||
| ADP receptors of platelets and their inhibition | Q74314926 | ||
| The antiplatelet effects of ticlopidine and clopidogrel | Q77292679 | ||
| Alterations of adenine nucleotide metabolism and function of blood platelets in patients with diabetes | Q79678239 | ||
| A double-blind, randomized study on platelet aggregation in patients treated with a daily dose of 150 or 75 mg of clopidogrel for 30 days | Q79710766 | ||
| The greater in vivo antiplatelet effects of prasugrel as compared to clopidogrel reflect more efficient generation of its active metabolite with similar antiplatelet activity to that of clopidogrel's active metabolite | Q80209388 | ||
| Assessment of ADP-induced platelet aggregation with light transmission aggregometry and multiple electrode platelet aggregometry before and after clopidogrel treatment | Q80543316 | ||
| Functional impact of high clopidogrel maintenance dosing in patients undergoing elective percutaneous coronary interventions. Results of a randomized study | Q80543338 | ||
| The use of the VerifyNow P2Y12 point-of-care device to monitor platelet function across a range of P2Y12 inhibition levels following prasugrel and clopidogrel administration | Q80710251 | ||
| Insulin-like growth factor-1 potentiates platelet activation via the IRS/PI3Kalpha pathway | Q81163093 | ||
| ADP-induced platelet aggregation and platelet reactivity index VASP are good predictive markers for clinical outcomes in non-ST elevation acute coronary syndrome | Q81445965 | ||
| Effect of CYP2C19*2 and *3 loss-of-function alleles on platelet reactivity and adverse clinical events in East Asian acute myocardial infarction survivors treated with clopidogrel and aspirin | Q82300414 | ||
| Impact of cytochrome P450 2C19*2 polymorphism on intra-stent thrombus after drug-eluting stent implantation in Japanese patients receiving clopidogrel | Q82566275 | ||
| Combined influence of proton-pump inhibitors, calcium-channel blockers and CYP2C19*2 on on-treatment platelet reactivity and on the occurrence of atherothrombotic events after percutaneous coronary intervention. | Q33997642 | ||
| Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study | Q34009506 | ||
| Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy | Q34019082 | ||
| Efficacy and safety of intensified antiplatelet therapy on the basis of platelet reactivity testing in patients after percutaneous coronary intervention: systematic review and meta-analysis | Q34306772 | ||
| Platelet dysfunction in type 2 diabetes | Q34319534 | ||
| Platelet function analyzer (PFA-100): a tool to quantify congenital or acquired platelet dysfunction | Q34350327 | ||
| Cangrelor: an emerging therapeutic option for patients with coronary artery disease | Q34395970 | ||
| Individualising dual antiplatelet therapy after percutaneous coronary intervention: the IDEAL-PCI registry | Q34439089 | ||
| Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis | Q34564576 | ||
| Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel | Q34568130 | ||
| Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial | Q34622955 | ||
| Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease | Q34633709 | ||
| Morphine decreases clopidogrel concentrations and effects: a randomized, double-blind, placebo-controlled trial | Q34658201 | ||
| Low responsiveness to clopidogrel increases risk among CKD patients undergoing coronary intervention | Q34726838 | ||
| Genetic determinants of response to clopidogrel and cardiovascular events | Q34910210 | ||
| Cytochrome p-450 polymorphisms and response to clopidogrel | Q34910228 | ||
| Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study | Q34910745 | ||
| Evaluation of clinical risk factors to predict high on-treatment platelet reactivity and outcome in patients with stable coronary artery disease (PREDICT-STABLE). | Q35208684 | ||
| Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention | Q35610354 | ||
| Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group | Q36244558 | ||
| Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction: the randomized, double-blind, placebo-controlled IMPRESSION trial | Q36460862 | ||
| Platelet activation and atherothrombosis | Q37031278 | ||
| Cell adhesion mechanisms in platelets | Q37049884 | ||
| Platelet ADP-receptor antagonists for cardiovascular disease: past, present and future | Q37310828 | ||
| Antiplatelet therapy in diabetes: efficacy and limitations of current treatment strategies and future directions | Q37428365 | ||
| Ticagrelor--a new platelet aggregation inhibitor in patients with acute coronary syndromes. An improvement of other inhibitors? | Q37641001 | ||
| Effect of proton pump inhibitors on clinical outcome in patients treated with clopidogrel: a systematic review and meta-analysis. | Q37787305 | ||
| Functional testing methods for the antiplatelet effects of aspirin | Q37841562 | ||
| Diabetes and antiplatelet therapy in acute coronary syndrome. | Q37846051 | ||
| Ischaemic and bleeding complications with new, compared to standard, ADP-antagonist regimens in acute coronary syndromes: a meta-analysis of randomized trials | Q37875612 | ||
| TRITON and beyond: new insights into the profile of prasugrel | Q37925009 | ||
| Pharmacokinetic basis of the antiplatelet action of prasugrel | Q37927151 | ||
| Pharmacokinetic, pharmacodynamic and pharmacogenetic profile of the oral antiplatelet agent ticagrelor | Q38001453 | ||
| The evolution of antiplatelet therapy in the treatment of acute coronary syndromes: from aspirin to the present day. | Q38053481 | ||
| A critical overview on ticagrelor in acute coronary syndromes | Q38055461 | ||
| Antiplatelet treatment for prevention of cerebrovascular events in patients with vascular diseases: a systematic review and meta-analysis | Q38173831 | ||
| Clinical implications of drug-drug interactions with P2Y12 receptor inhibitors | Q38177048 | ||
| Off-target effects of glycoprotein IIb/IIIa receptor inhibitors | Q38187933 | ||
| Novel antiplatelet agents in acute coronary syndrome | Q38257119 | ||
| Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation | Q38375573 | ||
| Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction | Q38460956 | ||
| Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy | Q38461756 | ||
| Paraoxonase-1 Q192R polymorphism and antiplatelet effects of clopidogrel in patients undergoing elective coronary stent placement. | Q38489276 | ||
| Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial | Q38493350 | ||
| Switching P2Y12-receptor inhibitors in patients with coronary artery disease | Q38568711 | ||
| Ticagrelor inhibits adenosine uptake in vitro and enhances adenosine-mediated hyperemia responses in a canine model | Q39519989 | ||
| Clinical, angiographic, and genetic factors associated with early coronary stent thrombosis | Q39693579 | ||
| Relation of cytochrome P450 2C19 loss-of-function polymorphism to occurrence of drug-eluting coronary stent thrombosis. | Q39996910 | ||
| Bivalirudin and clopidogrel with and without eptifibatide for elective stenting: effects on platelet function, thrombelastographic indexes, and their relation to periprocedural infarction results of the CLEAR PLATELETS-2 (Clopidogrel with Eptifibati | Q40000958 | ||
| P2Y12 Receptor Inhibitors in Acute Coronary Syndromes: What Is New on the Horizon? | Q41511099 | ||
| A multiple dose study of prasugrel (CS-747), a novel thienopyridine P2Y12 inhibitor, compared with clopidogrel in healthy humans | Q41868121 | ||
| Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial | Q42164176 | ||
| Effects of CYP2C19 genotype on outcomes of clopidogrel treatment | Q42846150 | ||
| Cytochrome P450 2C19 polymorphism, suboptimal reperfusion and all-cause mortality in patients with acute myocardial infarction | Q42869136 | ||
| Genetic variability in response to clopidogrel therapy: clinical implications | Q42905464 | ||
| CYP2C19*2 and CYP2C9*3 alleles are associated with stent thrombosis: a case-control study | Q42910083 | ||
| Protective effect of the CYP2C19 *17 polymorphism with increased activation of clopidogrel on cardiovascular events | Q42913374 | ||
| Platelet aggregation and its association with stent thrombosis and bleeding in clopidogrel-treated patients: initial evidence of a therapeutic window | Q42969238 | ||
| Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement | Q43051165 | ||
| Dual low response to acetylsalicylic acid and clopidogrel is associated with myonecrosis and stent thrombosis after coronary stent implantation | Q43077318 | ||
| Relationship between platelet reactivity inhibition and non-CABG related major bleeding in patients undergoing percutaneous coronary intervention | Q43174983 | ||
| Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement | Q43190644 | ||
| Pantoprazole may enhance antiplatelet effect of enteric-coated aspirin in patients with acute coronary syndrome. | Q43233276 | ||
| Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement | Q43234546 | ||
| Multiple electrode aggregometry predicts stent thrombosis better than the vasodilator-stimulated phosphoprotein phosphorylation assay | Q43234549 | ||
| A comparison of platelet function tests and thromboxane metabolites to evaluate aspirin response in healthy individuals and patients with coronary artery disease | Q50199243 | ||
| The use of amlodipine, but not of P-glycoprotein inhibiting calcium channel blockers is associated with clopidogrel poor-response | Q50199244 | ||
| The significance of vasodilator-stimulated phosphoprotein for risk stratification of stent thrombosis. | Q50847978 | ||
| Platelet inhibition by abciximab bolus-only administration and oral ADP receptor antagonist loading in acute coronary syndrome patients: the blocking and bridging strategy. | Q50887397 | ||
| Genetic variation of platelet function and pharmacology: an update of current knowledge. | Q50965674 | ||
| How to improve the concept of individualised antiplatelet therapy with P2Y12 receptor inhibitors--is an algorithm the answer? | Q51036458 | ||
| The net clinical benefit of personalized antiplatelet therapy in patients undergoing percutaneous coronary intervention. | Q51063040 | ||
| Monitoring survival and function of transfused platelets in Bernard-Soulier syndrome by flow cytometry and a cone and plate(let) analyzer (Impact-R). | Q51088245 | ||
| Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. | Q51109075 | ||
| Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation. | Q51127260 | ||
| Hirudin anticoagulation allows more rapid determination of P2Y₁₂ inhibition by the VerifyNow P2Y12 assay. | Q51277912 | ||
| Why have studies of tailored anti-platelet therapy failed so far? | Q51795662 | ||
| Association of cytochrome P450 2C19*2 polymorphism with clopidogrel response variability and cardiovascular events in Koreans treated with drug-eluting stents. | Q53418798 | ||
| The relationship between CYP2C19 polymorphisms and ischaemic and bleeding outcomes in stable outpatients: the CHARISMA genetics study | Q53461746 | ||
| Vasodilator-stimulated phosphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events. | Q53554561 | ||
| No association of ABCB1 C3435T genotype with clopidogrel response or risk of stent thrombosis in patients undergoing coronary stenting. | Q53672191 | ||
| Pharmacodynamic evaluation of switching from ticagrelor to prasugrel in patients with stable coronary artery disease: Results of the SWAP-2 Study (Switching Anti Platelet-2). | Q54447617 | ||
| Prasugrel or double-dose clopidogrel to overcome clopidogrel low-response--the TAILOR (Thrombocytes And IndividuaLization of ORal antiplatelet therapy in percutaneous coronary intervention) randomized trial. | Q54580380 | ||
| Prasugrel versus ticagrelor in acute coronary syndrome: a randomized comparison. | Q54600153 | ||
| 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiol | Q55056448 | ||
| Effect of Paraoxonase-1 Polymorphism on Clinical Outcomes in Patients Treated With Clopidogrel After an Acute Myocardial Infarction | Q57243379 | ||
| Impact of Insulin Receptor Substrate-1 Genotypes on Platelet Reactivity and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease | Q57764490 | ||
| Personalized antiplatelet treatment after percutaneous coronary intervention: The MADONNA study | Q58071003 | ||
| Phenotyping vs. genotyping for prediction of clopidogrel efficacy and safety: the PEGASUS-PCI study | Q58071120 | ||
| CYP2C19 But Not PON1 Genetic Variants Influence Clopidogrel Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy in Post–Myocardial Infarction Patients | Q60018251 | ||
| Comparison of the antiplatelet effect of two clopidogrel bisulfate formulations: Plavix and generic-Egitromb | Q60189773 | ||
| Time-related changes in determinants of antiplatelet effect of clopidogrel in patients after myocardial infarction | Q60189807 | ||
| Prasugrel overcomes high on-clopidogrel platelet reactivity in the acute phase of acute coronary syndrome and maintains its antiplatelet potency at 30-day follow-up | Q60189859 | ||
| Ticagrelor, but not clopidogrel and prasugrel, prevents ADP-induced vascular smooth muscle cell contraction: A placebo-controlled study in rats | Q60189923 | ||
| Diurnal variation in platelet inhibition by clopidogrel | Q60190017 | ||
| Predictors of antiplatelet response to prasugrel during maintenance treatment | Q60195438 | ||
| No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting | Q60195531 | ||
| AMP-activated protein kinase (AMPK) regulates the insulin-induced activation of the nitric oxide synthase in human platelets | Q60760894 | ||
| Relationship between paraoxonase Q192R gene polymorphism and on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention | Q61402343 | ||
| Prognostic value of serial platelet reactivity measurements on long-term clinical outcome in patients with ST-elevation myocardial infarction undergoing primary PCI | Q61402668 | ||
| Influence of CYP2C19 Polymorphisms in Platelet Reactivity and Prognosis in an Unselected Population of Non ST Elevation Acute Coronary Syndrome | Q62090494 | ||
| Comparison of Prasugrel and Ticagrelor Loading Doses in ST-Segment Elevation Myocardial Infarction Patients | Q63342280 | ||
| Agranlocytosis caused by ticlopindine and its mechanism | Q67924218 | ||
| Effects of insulin on calcium metabolism and platelet aggregation | Q71258054 | ||
| Transmission of a procoagulant signal from tissue factor-bearing cell to platelets | Q71612091 | ||
| Platelets from diabetic subjects show diminished sensitivity to prostacyclin | Q71634275 | ||
| Inhibition of integrin-mediated platelet aggregation, fibrinogen-binding, and interactions with extracellular matrix by nonpeptidic mimetics of Arg-Gly-Asp | Q72381191 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 259-80 | |
| P577 | publication date | 2015-01-01 | |
| P1433 | published in | Postępy w Kardiologii Interwencyjnej | Q26853806 |
| P1476 | title | Personalized antiplatelet therapy with P2Y12 receptor inhibitors: benefits and pitfalls | |
| P478 | volume | 11 |
| Q42700913 | Abciximab as a bridging strategy to overcome morphine-prasugrel interaction in STEMI patients |
| Q28072522 | Antithrombotic management in patients with percutaneous coronary intervention requiring oral anticoagulation |
| Q38818086 | Comparison of Ticagrelor Pharmacokinetics and Pharmacodynamics in STEMI and NSTEMI Patients (PINPOINT): protocol for a prospective, observational, single-centre study. |
| Q47161058 | Factors related to on-treatment platelet aggregation assessed by multiple electrode aggregometry in percutaneous coronary intervention patients on clopidogrel and aspirin. |
| Q47160727 | Genetic testing in antiplatelet therapy - not effective for perioperative bleeding. |
| Q92502611 | Incidence, predictors, and prognosis of premature discontinuation or switch of prasugrel or ticagrelor: the ATLANTIS - SWITCH study |
| Q49639946 | Long-Term Percutaneous Coronary Intervention Outcomes of Patients with Chronic Kidney Disease in the Era of Second-Generation Drug-Eluting Stents. |
| Q36216424 | Platelet aggregation and risk of stent thrombosis or bleeding in interventionally treated diabetic patients with acute coronary syndrome. |
| Q92438951 | Platelet reactivity patterns in patients treated with dual antiplatelet therapy |
| Q39419192 | Platelets redox balance assessment: Current evidence and methodological considerations. |
| Q41405409 | Predictors of high on-aspirin platelet reactivity in elderly patients with coronary artery disease |
| Q39198400 | Second-generation drug-eluting stents in the elderly patients with acute coronary syndrome: the in-hospital and 12-month follow-up of the all-comer registry |
| Q92075011 | Stratified Approaches to Antiplatelet Therapies Based on Platelet Reactivity Testing |
| Q90151481 | Ticagrelor versus clopidogrel in the management of acute myocardial infarction |
| Q37463805 | Triple anticoagulation therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention - real life assessment |
Search more.